Portfolio Press Release
Solace Pharmaceuticals Co-Founder and Scientific Advisory Board Member Joyce DeLeo Receives the Prestigious 2009 Kerr Award
Solace Pharmaceuticals Press Release
3 June 2009
June 3rd 2009 — Joyce DeLeo, PhD, the Irene Heinz Given Professor of Pharmacology and Anesthesiology, Chair of Pharmacology and Toxicology and Director of the Neuroscience Center at Dartmouth University Medical School as well as co-founder and Scientific Advisory Board member of Solace Pharmaceuticals, has received the 2009 Frederick W.L. Kerr Basic Science Research Award at the annual meeting of the American Pain Society, held May 7-9, 2009 in San Diego, California.
The Frederick W.L. Kerr Basic Science Research Award, named for the founder of the American Pain Society, has been awarded every year since 1987 to recognize individual excellence and achievements in clinical pain scholarship. Joyce DeLeo was honored particularly for her work elucidating the role of glial cells in pain. "We extend our warmest congratulations to Joyce DeLeo on receiving the 2009 Kerr Award. Joyce has produced an extraordinary body of work in glial cell biology that lays the foundation for an entirely new approach to discovery and development of drugs for pain and neuro-inflammatory conditions. Solace is greatly enriched by Joyce's contributions as a co-founder and member of the Scientific Advisory Board," said Eliot Forster, PhD MBA, Solace Pharmaceuticals' Chief Executive Officer.
Joyce joins Tony L. Yaksh, PhD, Allan I. Basbaum, PhD and David Julius, PhD as other members of Solace Pharmaceuticals' Scientific Advisory Board who have received the Kerr Award.
About Solace Pharmaceuticals
Solace Pharmaceuticals discovers and develops innovative treatments for pain. Solace's research and development programs are focused on exploiting novel biological understanding of disease targets that play a role in the pathogenesis of pain and that have disease-modifying potential in two key areas: modulating the activity of glial cells and intervening in the tetrohydrobiopterin (BH4) pathway. SLC022, the company's lead drug candidate, is in phase II clinical development in patients with post-herpetic neuralgia (PHN). Solace's research and development are supported by a strong and expanding intellectual property portfolio. For more information, please visit the company's website at www.solacepharma.com.
